What's Happening?
Wacker has announced the launch of contract research services (CRS) at its biotech center in Munich, focusing on R&D-grade plasmid DNA (pDNA), RNA, and lipid nanoparticles (LNPs) for preclinical studies. This new service complements the offerings of Wacker Biotech,
which operates in Germany, the Netherlands, and the U.S. The CRS team provides construct design services, including plasmid and RNA construct design, RNA engineering, and optimization. They also conduct lipid library screening and LNP formulation, along with functional assays and analytical services. The initiative aims to streamline development and reduce supply-chain fragmentation, offering a faster path from design to delivery in advanced therapies. The service is particularly beneficial for small startups, as it reduces the high costs associated with developing small amounts of drug substances for R&D studies. One of the first customers is SRTD Biotech, which is working on novel therapeutic approaches using selectively expressed RNAs (seRNAs).
Why It's Important?
The launch of Wacker's CRS is significant for the biotech industry as it addresses the high costs and complexities involved in early-stage drug development. By providing a comprehensive suite of services, Wacker enables smaller biotech companies to advance their research without the prohibitive costs typically associated with drug development. This could lead to more innovative therapies reaching the market, particularly in the field of nucleic acid-based therapies, which are gaining traction for their potential in treating a variety of diseases. The integration of early-stage R&D support with a global GMP manufacturing network also ensures a smoother transition from research to clinical trials, potentially accelerating the development of life-saving therapies.
